Surrozen, Inc.

NASDAQ
SRZN
paper.types.company
Rentabilité sur six mois: -35.34%
Rendement en dividendes: 0%
Secteur: Healthcare

7.89 $

+0.238 $ +3.11%
6.5 $
17.02 $

paper.min_max_per_year

Calendrier des promotions Surrozen, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Surrozen, Inc.

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. The company is developing antibody-based therapeutics with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.

plus de détails
Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcoholic hepatitis and asialoglycoprotein receptor 1; and SZN-1326, a bi-specific antibody, which is in Phase 1b clinical trial for the treatment of moderate to severe inflammatory bowel disease, Frizzled, and LRP receptors. The company also develops SZN-413, a Fzd4 targeted bi-specific antibody, which is in preclinical stage for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. was founded in 2015 and is based in South San Francisco, California.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Paramètres de base

IPO date
2021-01-11
ISIN
US86889P1093
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
lien
Tous les paramètres

Grade

Sous-estimation
Nom Signification Grade
P/S 1.35 9
P/BV 0.4458 10
P/E 0 0
Efficacité
Nom Signification Grade
ROA -93.41 0
ROE -113.46 0
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA -0.0822 10
Debt/Ratio 0.0733 10
Debt/Equity 0.2147 10
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % 0 0
Rentabilité Ebitda, % 80.4 9
Rentabilité EPS, % 416.44 10
Plus de détails

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 7.65 $ 0 $ 0 $ 3.11 % 0 % 0 %
common.calendar.number_days.7d 8.14 $ 0 $ 0 $ -3.1 % 0 % 0 %
common.calendar.number_days.30d 10.44 $ 6.85 $ 8.47 $ -24.43 % 0 % 0 %
common.calendar.number_days.90d 11.84 $ 6.5 $ 12.45 $ -33.38 % 0 % 0 %
common.calendar.number_days.180d 12.2 $ 6.5 $ 17.02 $ -35.34 % 0 % 0 %
common.calendar.number_days.1y 11 $ 6.5 $ 17.02 $ -28.29 % 0 % 0 %
common.calendar.number_days.3y 2.55 $ 0.331 $ 17.02 $ 209.33 % 0 % 0 %
common.calendar.number_days.5y 0 $ 0.331 $ 17.02 $ 0 % 0 % 0 %
common.calendar.number_days.10y 0 $ 0.331 $ 17.02 $ 0 % 0 % 0 %
common.calendar.number_days.ytd 9.52 $ 6.5 $ 17.02 $ -17.14 % 0 % 0 %

Principaux propriétaires

Entreprises similaires

P/E & P/BVEV/Ebitda & Debt/Ebitda


Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Mr. Craig C. Parker M.B.A. CEO, President & Director 825.32k 1962 (63 année)
Mr. Charles Williams CFO, COO & Corporate Secretary 611.03k 1980 (45 années)
Dr. K. Christopher Garcia Ph.D. Co-Founder & Member of Scientific Advisory Board N/A
Dr. Roeland Nusse Ph.D. Co-Founder & Member of Scientific Advisory Board N/A 1950 (75 années)
Dr. Calvin Kuo M.D., Ph.D. Co-Founder & Member of Scientific Advisor N/A
Dr. Li Yang Ph.D. Executive Vice President of Research 535.46k 1969 (56 années)
Esther Jhun Controller N/A

Informations sur l'entreprise

Adresse: United States, South San Francisco. CA, 171 Oyster Point Boulevard - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.surrozen.com